Volume 1 Issue 3
Dec.  2022
Turn off MathJax
Article Contents
Article Navigation >  Clinical Cancer Bulletin  > 2022  >  1(3): 160-163
Qingliang JIANG, Jie TANG, Xianglin LIU, Yingjie JIANG, Yanfang LIU, Hengyu LI. DESTINY-Breast04: Calm Thinking on the HER2-low[J]. Clinical Cancer Bulletin, 2022, 1(3): 160-163. doi: 10.11910/j.issn.2791-3937.2022.20220027
Citation: Qingliang JIANG, Jie TANG, Xianglin LIU, Yingjie JIANG, Yanfang LIU, Hengyu LI. DESTINY-Breast04: Calm Thinking on the HER2-low[J]. Clinical Cancer Bulletin, 2022, 1(3): 160-163. doi: 10.11910/j.issn.2791-3937.2022.20220027
shu

DESTINY-Breast04: Calm Thinking on the HER2-low

doi: 10.11910/j.issn.2791-3937.2022.20220027
  • 1.

    The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China

  • 2.

    Daiichi Sankyo (China) Holdings Co., Ltd., Shanghai 200040, China

More Information
    Abstract
    • FullText(HTML)
  • loading

    • None.

    References(10)
  • [1]
    Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. New England Journal of Medicine, 2022, 387(1): 9–20. doi: 10.1056/NEJMoa2203690
    [2]
    Shui R, Liang X, Li X, et al. Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12, 467 Patients From 19 Chinese Representative Clinical Centers. Clinical Breast Cancer,, 2020, 20(1): e65–e74. doi: 10.1016/j.clbc.2019.07.013
    [3]
    Romond E H, Perez E A, Bryant J, et al. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. New England Journal of Medicine, 2005, 353(16): 1673–1684. doi: 10.1056/NEJMoa052122
    [4]
    Diéras V, Deluche E, Lusque A, et al. Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY). Cancer Research, 2022, 82(4_Supplement): D2–D8. doi: 10.1158/1538-7445.SABCS21-PL2
    [5]
    Schettini F, Chic N, Brasó-Maristany F, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer, 2021, 7(1): 1. doi: 10.1038/s41523-020-00208-2
    [6]
    Fernandez A I, Liu M, Bellizzi A, et al. Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. JAMA Oncol, 2022, 8(4): 1–4.
    [7]
    Zhang G, Ren C, Li C, et al. Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status. BMC Medicine, 2022, 20(1): 142. doi: 10.1186/s12916-022-02346-9
    [8]
    Tarantino P, Jin Q, Tayob N, et al. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. JAMA Oncol, 2022, 8(8): 1177–1183.
    [9]
    Bardia A, Tolaney S M, Loirat D, et al. Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study. Journal of Clinical Oncology, 2022, 40(16_suppl): 1071. doi: 10.1200/JCO.2022.40.16_suppl.1071
    [10]
    Rugo H S, Bardia A, Tolaney S M, et al. TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR + /HER2− metastatic breast cancer. Future Oncology, 2020, 16(12): 705–715. doi: 10.2217/fon-2020-0163
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article Views(161) PDF Downloads(12) Cited by()
    Proportional views
    Related

    Contacts

    Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return